Loading
Mucinous adenocarcinoma is a form of bowel cancer, about one in ten cases, in which more than half the tumour is made of mucus produced by the cancer cells. It favours the right side of the colon, is often mismatch-repair deficient, tends to be found at a later stage and does somewhat worse than ordinary bowel cancer, but it is treated the same way.
The WHO classification defines mucinous adenocarcinoma by extracellular mucin making up more than 50 percent of the tumour, and grades it by its mismatch repair status rather than by gland formation (Nagtegaal 2020). In the Munich registry of 28,056 patients, mucinous adenocarcinoma made up 9.7 percent of colorectal cancers and was located in the proximal colon in 57 percent of cases against 34 percent of ordinary adenocarcinoma, was diagnosed at more advanced stages and had reduced survival (J Cancer Res Clin Oncol 2016). In 9,494 SEER patients with mucinous against 107,735 with non-mucinous adenocarcinoma, mucinous tumours occurred in older patients and were larger and more often of moderate grade, and surgery improved survival (Annals of Translational Medicine 2020). The meta-analysis of 1,087,055 patients found mucinous carcinoma more often right-sided than adenocarcinoma and with reduced five-year overall survival (Discover Oncology 2021).
How it differs from its parent: site, stage at diagnosis, frequent mismatch repair deficiency and a weaker response to some chemotherapy in older series; management nonetheless follows the colorectal page by stage and molecular status, with mismatch repair status deciding immunotherapy.
How common: about 10 percent (Discover Oncology 2021; J Cancer Res Clin Oncol 2016).
Treatment: as the parent, by stage and mismatch repair status (surgery, FOLFOX or CAPOX, checkpoint inhibitors for MSI-high disease); the sources read are registry and pathology studies, not trials in the type.
About 10 percent of colorectal cancers: 110,179 of 1,087,055 patients (10.13 percent) in a meta-analysis of 30 studies (Discover Oncology 2021) and 2,724 of 28,056 (9.7 percent) in the Munich registry (J Cancer Res Clin Oncol 2016).
Right-sided tumours behave differently from left-sided and rectal ones; the colon drains along its mesenteric vessels, the rectum into the mesorectum and pelvic side wall.
Same organ: Colon cancer (adenocarcinoma of the colon), Signet ring cell carcinoma of the colon and rectum, Medullary carcinoma of the colon, Serrated adenocarcinoma of the colon and rectum, Peritoneal mesothelioma, Colorectal cancer, Rectal cancer, Mismatch-repair deficient (MSI-high) colorectal cancer, BRAF V600E-mutant colorectal cancer, HER2-amplified colorectal cancer, KRAS G12C-mutant colorectal cancer, Early-onset colorectal cancer (under 50), Anal cancer (squamous cell carcinoma), Appendiceal cancer and pseudomyxoma peritonei, Small intestine cancer (small bowel adenocarcinoma), Small intestinal neuroendocrine tumours, Anal high-grade squamous intraepithelial lesions (precursor), Localised anal squamous cell carcinoma (stage I to III), Metastatic and recurrent anal squamous cell carcinoma, Low-grade appendiceal mucinous neoplasm and pseudomyxoma peritonei, Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell), Goblet cell adenocarcinoma of the appendix, Localised small bowel adenocarcinoma (stage I to III, resected), Advanced and metastatic small bowel adenocarcinoma
Treated as the colorectal page by stage and mismatch repair status.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this cancer: (TITLE:"Mucinous adenocarcinoma of the colon and rectum" OR ABSTRACT:"Mucinous adenocarcinoma of the colon and rectum" OR TITLE:"Mucinous colorectal cancer" OR ABSTRACT:"Mucinous colorectal cancer" OR TITLE:"Colloid carcinoma of the colon" OR ABSTRACT:"Colloid carcinoma of the colon" OR TITLE:"Mucinous adenocarcinoma of the colon" OR ABSTRACT:"Mucinous adenocarcinoma of the colon" OR TITLE:"Mucinous carcinoma of the colorectum" OR ABSTRACT:"Mucinous carcinoma of the colorectum") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Mucinous adenocarcinoma of the colon and rectum, not a curated reading list.
The targets of this cancer's medicines and the ones linked to it directly.
Cases by country, the UK and NHS pathway and other country lenses, and the expert centres with trials on record.
One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.
Bleeding that will not stop, black or bloody stools, or unexplained bruising when platelets are expected to be low.
Persistent headache with extreme tiredness, nausea, dizziness on standing or low blood pressure. Vomiting, severe weakness or collapse is adrenal crisis.
No pharmacokinetic interactions expected (antibody). See the irAE guide for toxicity management.
Immunotherapy can attack hormone-producing glands: most often the thyroid (usually ending in an under-active thyroid needing lifelong tablets), and less often the pituitary (hypophysitis) or adrenal glands, which can be life-threatening if missed.
See all on the product pages:FOLFOX (5-FU, leucovorin, oxaliplatin)Pembrolizumab·Printable cards in the navigator
Newly diagnosed? Read the first 60 days with Mucinous adenocarcinoma of the colon and rectum, then print the one-page appointment sheet with room for the answers.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.